Asprosin levels in patients with type 2 diabetes mellitus, metabolic syndrome and obesity: A systematic review and meta-analysis

• Autores: Ulloque-Badaracco, Juan R., Al-kassab-Córdova, Ali, Hernandez-Bustamante, Enrique A., Alarcon-Braga, Esteban A., Robles-Valcarcel, Pamela, Huayta-Cortez, Miguel A., Cabrera Guzmán, Juan C., Seminario-Amez, Rosa A., Benites-Zapata, Vicente A.
• Formato: artículo
• Fecha de Publicación: 2024
• Institución: Universidad Peruana de Ciencias Aplicadas
• Repositorio: UPC-Institucional
• Lenguaje: inglés
• OAI Identifier: oai:repositorioacademico.upc.edu.pe:10757/675810
• Enlace del recurso: http://hdl.handle.net/10757/675810
• Nivel de acceso: acceso embargado
• Materia: Asprosin; Diabetes mellitus; Metabolic diseases; Metabolic syndrome; Obesity

Background & aims: Asprosin is a promising candidate for novel treatments for metabolic–endocrine disorders. The objective of this systematic review and meta-analysis was to consolidate the existing evidence regarding asprosin levels in patients diagnosed with type 2 diabetes (T2D), metabolic syndrome (MetS), and obesity. Methods: Scopus, Embase, PubMed, Ovid/Medline, and Web of Science were systematically searched without restrictions. We only used the standardized mean differences (SMD) with their 95 % confidence intervals (95 % CI) as the effect measure. A random-effects model (DerSimonian and Laird method) was used for the meta-analysis. Risk of bias was assessed with the Newcastle–Ottawa Scale and Newcastle–Ottawa Scale for Cross-Sectional Studies. Results: Twenty-six studies (n = 3,787) were included in the meta-analysis. Participants with T2D had higher asprosin values than those without T2D (SMD: 1.64; 95 % CI: 1.08–2.21; I2 = 97 %). Patients with MetS had higher asprosin levels compared to those without MetS (SMD: 0.99; 95 % CI: 0.34–1.64; I2 = 96 %). Patients with obesity had higher asprosin levels than participants without obesity (SMD: 1.49; 95 % CI: 0.23–2.76; I2 = 98 %). Conclusions: Asprosin is significantly higher in patients with either T2D, MetS, or obesity, compared with controls.